A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Show other versions (1)

Manylion Llyfryddiaeth
Prif Awduron:	Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M
Fformat:	Journal article
Cyhoeddwyd:	2011

Eitemau Tebyg

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
gan: Leijen, S, et al.
Cyhoeddwyd: (2011)

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
gan: Gupta, A, et al.
Cyhoeddwyd: (2013)

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
gan: Dummer, R, et al.
Cyhoeddwyd: (2008)

MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
gan: Takahashi, O, et al.
Cyhoeddwyd: (2009)

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
gan: Jin-Hang Gao, et al.
Cyhoeddwyd: (2022-03-01)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
gan: Kirkwood, J, et al.
Cyhoeddwyd: (2012)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
gan: Edmund Poon, et al.
Cyhoeddwyd: (2017-08-01)

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
gan: Gupta, A, et al.
Cyhoeddwyd: (2014)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
gan: K. Haslett, et al.
Cyhoeddwyd: (2021-05-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
gan: Andrea Gazzin, et al.
Cyhoeddwyd: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
gan: Tahar Sif eddine Bouchema, et al.
Cyhoeddwyd: (2022-11-01)

Effect of food on capsule and granule formulations of selumetinib
gan: Sarit Cohen‐Rabbie, et al.
Cyhoeddwyd: (2022-04-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
gan: Pacey, S, et al.
Cyhoeddwyd: (2016)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
gan: Appels, N, et al.
Cyhoeddwyd: (2008)

Computer interfacing with radial line slot arry (RLSA) antenna measurement /
gan: 254621 Chin, Wen Sing
Cyhoeddwyd: (1999)

Monitoring and quantification of rural urbanisation: Case of Arris and Theniet Elabed, Algeria
gan: Soto Sabrina, et al.
Cyhoeddwyd: (2024-01-01)

In search of an architectural genome of traditional houses: Case of the habitat of the Dechras of Arris
gan: Aksas Samiha, et al.
Cyhoeddwyd: (2023-01-01)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
gan: Xiaohang Zheng, et al.
Cyhoeddwyd: (2022-09-01)

Fingerprint-fingervein multimodal biometric authentication system on field programmable gate arry /
gan: Chong, Yew Hoe, 1992-, et al.
Cyhoeddwyd: (2015)

Histopathologic features of selumetinib‐induced paronychia in a child with neurofibromatosis type 1
gan: P. Borgia, et al.
Cyhoeddwyd: (2024-06-01)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
gan: Woessner Richard, et al.
Cyhoeddwyd: (2009-07-01)

Selumetinib—A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis
gan: Surajit Gorai, et al.
Cyhoeddwyd: (2024-06-01)

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
gan: Leijen, S, et al.
Cyhoeddwyd: (2012)

Dual axis rotation solar irradiance tracking system for photovoltaic arry [electronic resource] /
gan: Thanikaikumaran R. Kuppusamy, 1987-, author 646957, et al.
Cyhoeddwyd: (2017)

The phenomenon of repetition according to Abu Al-Ala’ Al-Ma’arri in “The Chapters and Ends”
gan: زهره قرباني مادواني
Cyhoeddwyd: (2018-02-01)

Fingerprint-fingervein multimodal biometric authentication system on field programmable gate arry [electronic resource] /
gan: Chong, Yew Hoe, 1992-, et al.
Cyhoeddwyd: (2015)

An optical wavelength multi/demultiplexing (DWDM/CWDM) based arry waveguide grating (AWG) technique /
gan: 333366 Ismahayati Adam, et al.
Cyhoeddwyd: (2008)

<b>Peroxidase activity in <em>Spondias dulcis</em></b> - 10.4025/actascitechnol.v32i4.6244
gan: Dayse Pereira Barbosa Souza, et al.
Cyhoeddwyd: (2010-12-01)

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS
gan: Lin Li
Cyhoeddwyd: (2025-01-01)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
gan: Meng Xia, et al.
Cyhoeddwyd: (2021-01-01)

Normal Computed Tomography and Radiographic Study of the Nasal Cavity and Paranasal Sinuses in Shal Sheep (Ovis arries)
gan: Alireza Vajhi, et al.
Cyhoeddwyd: (2023-10-01)

P162: Changes of café-au-lait spots intensity by selumetinib in neurofibromatosis type I*
gan: Beomhee Lee, et al.
Cyhoeddwyd: (2024-01-01)

Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma
gan: Nigel Blackwood, et al.
Cyhoeddwyd: (2023-12-01)

POLARIZAÇÃO DE MACRÓFAGOS PARA O FENÓTIPO M1 UTILIZANDO PLINABULINA E SELUMETINIBE
gan: LHS Pinheiro, et al.
Cyhoeddwyd: (2023-10-01)

An optical wavelength multi/demultiplexing (DWDM/CWDM) based arry waveguide grating (AWG) technique [Electronic Resource] /
gan: 333366 Ismahayati Adam, et al.
Cyhoeddwyd: (2008)

ŞAiR EBU'L- ALA EL-MA'ARRi, HAYATI, ESERLERi VE EDEBi ANLAYlŞI
gan: Mustafa Kırkız
Cyhoeddwyd: (2011-06-01)

Sastra Arab dan Disabilitas: Pendekatan Ekspresif terhadap Puisi “al-Marsiyyah” Karya al-Ma’arri
gan: Tatik Mariyatut Tasnimah
Cyhoeddwyd: (2019-06-01)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
gan: Robert, C, et al.
Cyhoeddwyd: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
gan: Robert, C, et al.
Cyhoeddwyd: (2013)

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway.
gan: Chen Li, et al.
Cyhoeddwyd: (2016-01-01)